IP Library Granted Patent US 11,110,069
Granted Patent B2
US 11,110,069 · App. 16/671,469 · Granted Sep 7, 2021

Composition comprising cannabinoids for relief of pain

Inventors: Mark Andrew Hetherington (Toronto, CA); Chris Schnarr (Toronto, CA)
Assignee: TWEED INC.
A61K31/05A61K9/0014A61K31/165A61K31/192A61K31/196A61K31/606A61K36/28A61K36/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,069
App. No.
16/671,469
Granted
Sep 7, 2021
Kind
B2
Abstract

The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

Claims (27)

1. A composition for topical application comprising:

at least one purified cannabinoid, wherein the purified cannabinoid is cannabidiol (CBD);

at least one anti-inflammatory agent in an amount ranging from between about 10 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; and

at least one botanical extract, wherein the botanical extract is arnica.

2. The composition of claim 1 , further comprising a terpene or terpenoid.

3. The composition of claim 2 , wherein the terpene or terpenoid is menthol, camphor, or a combination thereof.

4. The composition of claim 2 , wherein the terpene is an isolate, an extract or a distillate.

5. The composition of claim 1 , further comprising a flavonoid, wherein the flavonoid is an isolate, an extract or a distillate.

6. The composition of claim 1 , wherein the purified cannabinoid is present in an amount ranging from between about 0.5 wt % and about 10 wt % of the total weight of the composition.

7. The composition of claim 1 , wherein the purified cannabinoid is present in an amount ranging from between about 2 wt % and about 8 wt % of the total weight of the composition.

8. The composition of claim 1 , wherein the purified cannabinoid is present in an amount ranging from between about 2 wt % and about 6 wt % of the total weight of the composition.

9. The composition of claim 1 , wherein the anti-inflammatory agent is present in an amount ranging from between about 10 wt % and about 25 wt % of the total weight of the composition.

10. The composition of claim 1 , wherein the anti-inflammatory agent is present in an amount ranging from between about 20 wt % and about 90 wt % of the total weight of the composition.

11. The composition of claim 1 , wherein the anti-inflammatory agent is present in an amount of, about 10 wt %, about 15 wt %, about 20 wt % or about 25 wt % of the total weight of the composition.

12. The composition of claim 1 , wherein the botanical extract is present in an amount ranging from between about 0.5 wt % and about 90 wt % of the total weight of the composition.

13. The composition of claim 1 , wherein the botanical extract is present in an amount ranging from between about 1 wt % and about 25 wt % of the total weight of the composition.

14. The composition of claim 1 , wherein the botanical extract is present in an amount ranging from between about 0.5 wt % and about 10 wt % of the total weight of the composition.

15. A composition for topical application comprising:

at least one purified cannabinoid in an amount of between about 0.5 wt % and about 10 wt % of the total weight of the composition, wherein the purified cannabinoid is cannabidiol (CBD);

at least one anti-inflammatory agent in an amount of and about 10 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; and

at least one botanical extract in an amount of between about 1 wt % and about 25 wt % of the total weight of the composition, wherein the botanical extract is arnica.

16. A composition for topical application comprising:

at least one purified cannabinoid, wherein the purified cannabinoid is cannabidiol (CBD);

at least one anti-inflammatory agent in an amount of between about 10 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate;

at least one botanical extract in an amount of between about 0.5 wt % and about 90 wt % of the total weight of the composition, wherein the botanical extract is arnica , and

a terpene or terpenoid, wherein the terpene or terpenoid is menthol, camphor, or a combination thereof.

17. A method for relieving pain in a subject, the method comprising administering to the subject the composition as defined in claim 1 .

Assignments (5)
SECURITY INTEREST Recorded Jan 20, 2026
From: CANOPY GROWTH CORPORATION; TWEED INC.
To: JGB COLLATERAL LLC
Reel/Frame 073521/0250 →
MERGER Recorded Jul 14, 2021
From: STARKCO HOLDINGS INC.
To: TWEED INC.
Reel/Frame 056920/0874 →
CHANGE OF NAME Recorded Mar 15, 2021
From: CANOPY HEALTH INNOVATIONS INC.
To: 10607410 CANADA INC.
Reel/Frame 055587/0165 →
ARTICLES OF CONTINUANCE Recorded Mar 15, 2021
From: 10607410 CANADA INC.
To: STARKCO HOLDINGS INC.
Reel/Frame 055588/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2020
From: HETHERINGTON, MARK ANDREW; SCHNARR, CHRIS
To: CANOPY HEALTH INNOVATIONS
Reel/Frame 053602/0290 →
Continuity (2)
Provisional Application 62754984 · Nov 2, 2018
Related Publication 20200138737A1 · May 7, 2020
Cited By (1)
US 12,280,145